Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1PtAGZ
via IFTTT
-
Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient...
-
Vaccine manufacturer Serum Institute of India (SSI) has filed a challenge to the Supreme Court against a 2016 amendment to the Income Tax Ac...
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
Search This Blog
Powered by Blogger.
Blog Archive
-
▼
2025
(210)
-
▼
April
(10)
- Kerala launches digital payment system, online ser...
- Now Pharma Inc looks for cure as Trump delivers do...
- People Tree Hospital Secures 25 Million USD (₹220 ...
- T-Rx: Indian pharma majors breathe easy as US spar...
- 'Pharma's exemption from reciprocal tariffs unders...
- Big relief for India! Trump spares pharma from har...
- Fortis healthcare buys disputed Fortis trademark f...
- Lupin acquires UK-based firm for 12.3 million pounds
- Market volatility derails Novartis' plan to sell s...
- 360 ONE, Claypond Capital get CCI nod to acquire s...
-
▼
April
(10)
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment